CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. First approved in 2021.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
CARBON DIOXIDE, USP is an inhaled gas product approved as an X-ray contrast agent for diagnostic imaging procedures. It functions by providing contrast activity to enhance radiographic visualization during pulmonary and cardiovascular imaging. This product represents a niche diagnostic modality with specialized clinical applications.
Peak lifecycle stage suggests stable commercial operations with established market presence; team size likely moderate given diagnostic positioning and niche indication.
X-Ray Contrast Activity
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury
Carbon Dioxide Investigation
Influence of Caffeine on Psychomotor Vigilance and Carbon Dioxide Tolerance During Graded Hypercapnia
RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Martin Pharmaceuticals is hiring 2 roles related to this product
Working on CARBON DIOXIDE, USP offers career development in diagnostic pharmaceutical commercialization and niche specialty healthcare markets. The peak lifecycle stage provides stability but limited growth upside; professionals should expect focus on market maintenance, key opinion leader relationships, and radiology department partnerships.